3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
12
Neoplasms
9
Prostatic Neoplasms
6
Multiple Myeloma
6
Fractures, Bone
4
Neoplasm Metastasis
3
Giant Cell Tumor of Bone
3
Carcinoma, Non-Small-Cell Lung
3
Bone Diseases, Metabolic
3
Spinal Cord Compression
2
Parathyroid Neoplasms
2
Osteoporosis
2
Lymphoma
2
Thyroid Neoplasms
1
Smoldering Multiple Myeloma
1
Recurrence
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplastic Processes
1
Neoplastic Cells, Circulating
1
Neoplasms, Plasma Cell
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hyperparathyroidism, Primary
1
Hypercalcemia
1
Interventions
Gemcitabine
153
Fluorouracil
45
Capecitabine
45
130-nm albumin-bound paclitaxel
43
Oxaliplatin
42
Albumin-Bound Paclitaxel
39
Leucovorin
31
Erlotinib Hydrochloride
30
pembrolizumab
23
Radiotherapy
22
Irinotecan
22
Radiosurgery
20
Bevacizumab
19
Docetaxel
17
Cyclophosphamide
17
Taxes
13
Cisplatin
13
Cetuximab
13
folfirinox
12
Nivolumab
11
Surgical Procedures, Operative
7
Paclitaxel
7
Ipilimumab
7
dehydroftorafur
6
Standard of Care
6
Radiation
6
Magnetic Resonance Spectroscopy
6
spartalizumab
5
ruxolitinib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pancreatic Neoplasms
×
Denosumab
×
Clear all
NCT04907851
2025-03-17
KEYNOTE-E86
Redx Pharma Ltd
Phase 2
Completed
45 enrolled
25 charts